Replies to post #623865 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

This is about poly-iclc. I asked the similar question about Flaskworks. My question was: is it possible that NWBO licensed Flaskworks to a company without triggering SEC filing? If that's the case, it could explain why Shashi left the company at the end of 2021. My understanding about maverick_1 reply post if I am not mistaken is that it is possible.

[beartrap12]

Hankmanhub, I'm sure you are correct that they haven't "tied up for all future commercial use after approval" with Oncovir for Hiltonol, but they obviously have an ordinary contract in place that doesn't require disclosure, as you note, and I would bet that they are about to sign a more comprehensive agreement that they will disclose. I don't know what it will look like. I don't know enough about how contracts/partnerships/etc. works in business. You know more than I do and I hope you keep posting your thoughts on their relationship with Oncovir, as well as other possible partners. Based on what our VP said on BigBiz a few months ago, it looks like NWBO will be partnering vs. selling out to BP in the near future.
Thanks, Hank

Bear, I do not agree. They may have had an agreement for use of poly in the trials. But I doubt they had one tied up for all future commercial use after approval. While ordinary contracts in the course of doing business do not require disclosure, any such far reaching contract (deal - however it is structured) IMO would be considered material and require disclosure. We have had no such disclosure, therefore I conclude that no such deal has been made as of yet.

[ATLnsider]

hankmanhub, I do not believe any deal or agreement would have to be disclosed until after DCVax-L is approved by 1 or more regulatory authority. If DCVax is not approved, then there would be no deal and no need to disclose.